INNATE PHARMA
IPH.PADrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Lacutamab | Phase 2 | Peripheral T Cell Lymphoma | - | - |
avdoralimab | Phase 2 | COVID | - | - |
Frequently asked questions
What is in INNATE PHARMA's drug pipeline?→
CatalystAlert tracks 2 drug candidates in INNATE PHARMA's (IPH.PA) pipeline across Phase 2. Its lead program is Lacutamab (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is INNATE PHARMA's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for INNATE PHARMA (IPH.PA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track IPH.PA biotech catalysts?→
Add IPH.PA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow INNATE PHARMA's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.